Positioned to deliver on the promise
of Treg therapeutics
Autoimmune and inflammatory diseases affect 100s of millions globally, we believe that leveraging Treg biology can lead to cures. GentiBio is developing engineered Tregs (EngTregs) to reset the body’s immune system, aiming to ameliorate autoimmune and acute inflammatory diseases
An experienced team with deep expertise in cell therapy, immunology and therapeutic development
Building autologous and allogeneic platforms that are robust, highly scalable and generate high purity EngTregs
With experienced CMC and Clinical teams able to make transformational therapies a reality for patients
GentiBio’s Tregs:
the future of immunology therapeutics
Our goal is to replace the need for systemic and less selective immune suppressive therapies and their associated risks. GentiBio’s engineered regulatory T-cell platform has a unique ability to potently suppress inflammation and autoimmune dysfunction in a tissue-restricted manner, while healing those damaged tissues, with the potential to reset a dysfunctional immune system and establish lasting immune homeostasis.
Our Investors
Founded on research by pioneers in the Treg, autoimmune disease and synthetic biology fields
GentiBio combines multiple technologies into a powerful, integrated Tregs engineering platform